NCCN Previews Chemotherapy Order Templates™
FORT WASHINGTON, Pa., May 30, 2008 — An initial set of NCCN Chemotherapy Order Templates™, peer-reviewed and evidence-based chemotherapy regimens with indications, doses, and schedules and routes of administration will be previewed at the upcoming American Society of Clinical Oncology (ASCO) meeting to be held May 31 to June 2, 2008.
The Templates can enhance patient safety by helping clinicians standardize patient care, reduce medication errors and anticipate and manage adverse events. They also include appropriate antiemetic and supportive care treatments, monitoring and safety patterns and supporting references. All clinical information in the Templates is derived from the recommendations of the NCCN Clinical Practice Guidelines in Oncology™ and the NCCN Drugs & Biologics Compendium™.
Access to the first set of NCCN Chemotherapy Order Templates™ will be provided via a flash-stick that can be obtained at the NCCN ASCO exhibit booth number 23015 and will include templates for the treatment of:
- Bladder Cancer
- Chronic Myelogenous Leukemia
- Kidney Cancer
- Prostate Cancer
Other templates for these and other cancer diagnoses will be made available on a rolling schedule throughout 2008 and 2009. All NCCN Chemotherapy Order Templates™ will be continually updated to reflect changes to the recommendations contained in the NCCN Clinical Practice Guidelines in Oncology™ and the NCCN Drugs & Biologics Compendium™.
For more information on the NCCN Chemotherapy Order Templates™, please contact Thomas Mitchell at 215-690-0245 or visit www.nccn.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin Carbone Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital